Business Insider
My Markets Watchlist
Markets Stocks

Novartis AG Stock , NVSEF

97.24 CHF -0.03 -0.03%
12:00:00 PM BRX
News Analyst Data Analyst Opinions Insider Activity Dividend Calendar


Novartis Stock Snapshot

226.33 B
Market Cap in USD
1.90 B
Number of Shares
1.90 B
Total Number of Shares
3.50
Dividend in CHF
3.95
Dividend Yield
17.02
P/E Ratio
89.07
Free Float in %
5.21
EPS in CHF
20.21
Book Value per Share in CHF
7.62
Cash Flow per Share in CHF

Historical Prices for Novartis

Loading..
Date Open Close Daily High Daily Low
Price change over selected period: 0% 0

Novartis Analyst Opinions

  • All
  • Buy
  • Hold
  • Sell
Date Analyst Rating Price

Novartis Estimates* in USD

  2025 2026 2027 2028 2029
Revenue 54,097 55,298 56,708 59,010 60,548
Dividend 4.04 4.20 4.36 4.46 4.92
Dividend Yield (in %) 3.43 % 3.57 % 3.71 % 3.79 % 4.18 %
EPS 8.59 8.94 9.54 10.42 11.09
P/E Ratio 13.69 13.15 12.33 11.28 10.60
EBIT 21,254 21,223 22,297 23,757 25,096
EBITDA 21,974 22,348 23,192 24,573 28,548
Net Profit 17,037 17,528 18,389 19,667 20,436
Net Profit Adjusted 17,037 17,528 18,389 19,667 20,436
Pre-Tax Profit 19,660 20,025 21,402 22,690 24,957
Pre-Tax Profit Reported 16,323 17,005 17,880 20,327 23,984
EPS (Non-GAAP) ex. SOE - - - - -
EPS (GAAP) 6.88 7.29 7.77 8.82 9.71
Gross Income 44,049 45,063 45,983 48,856 49,796
Cash Flow from Investing -3,021 -2,207 -2,389 -2,167 -2,139
Cash Flow from Operations 18,782 19,449 19,918 22,284 23,403
Cash Flow from Financing -14,320 -9,332 -10,667 -10,834 -11,129
Cash Flow per Share 9.06 9.56 10.03 11.67 14.20
Free Cash Flow 15,288 15,872 16,053 17,951 19,424
Free Cash Flow per Share 7.14 7.84 8.38 11.63 12.73
Book Value per Share 23.86 26.49 29.46 28.08 30.90
Net Debt 16,344 11,088 5,339 77 -4,497
Research & Development Exp. 10,009 10,233 10,433 10,660 10,846
Capital Expenditure 2,309 2,468 2,617 2,169 1,826
Selling, General & Admin. Exp. 13,104 13,004 12,990 13,220 13,298
Shareholder’s Equity 46,142 51,425 57,229 65,206 78,967
Total Assets 95,643 110,831 116,968 121,325 133,906
  Previous Quarter
ending 03/31/25 		Current Quarter
ending 06/30/25 		Next Quarter
ending 09/30/25 		Current Year
ending 12/31/25 		Next Year
ending 12/31/26
Earnings Estimates
No. of Analysts - 7 7 20 20
Average Estimate - 2.307 USD 2.117 USD 8.591 USD 8.942 USD
Year Ago - 1.444 USD 1.373 USD 5.210 USD -
Publish Date - 7/17/2025 10/28/2025 - -
Revenue Estimates
No. of Analysts - 6 6 19 18
Average Estimate - 13,996 USD 13,390 USD 54,097 USD 55,298 USD
Year Ago - 11,317 USD 11,111 USD 44,313 USD -
Publish Date - 7/17/2025 10/28/2025 - -
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Income Statements in Mio. CHF

2024 2023 2022 2021 2020 2019 2018
Sales 44,312.55 40,834.74 48,273.77 47,199.92 45,672.01 47,202.69 50,792.58
Change of sales in % 8.52 -15.41 2.28 3.35 -3.24 -7.07 5.08
Gross profit on sales 32,842.74 29,535.99 33,655.54 32,693.25 31,479.23 32,867.38 32,778.34
Gross profit on sales change in % 11.20 -12.24 2.94 3.86 -4.22 0.27 4.29
Operating income 13,586.06 10,664.30 11,712.92 10,607.32 10,154.86 10,029.26 9,540.00
Operating income change in % 27.40 -8.95 10.42 4.46 1.25 5.13 5.53
Income before tax 12,045.77 8,210.08 8,003.45 9,872.25 8,639.94 8,229.51 7,239.17
Income before tax change in % 46.72 2.58 -18.93 14.26 4.99 13.68 -6.79
Income after tax 10,516.05 7,699.65 6,642.48 21,961.59 7,576.49 7,097.60 12,341.91
Income after tax change in % 36.58 15.92 -69.75 189.86 6.75 -42.49 62.78

Balance Sheet in Mio. CHF

2024 2023 2022 2021 2020 2019 2018
Total liabilities 56,764.78 48,036.33 57,678.82 62,014.69 66,758.56 60,872.42 66,003.25
Long-term liabilities per share 15.58 12.63 14.70 15.43 16.63 14.79 15.93
Equity 39,989.19 39,347.14 54,978.16 61,796.02 50,089.91 53,792.81 77,574.57
Equity change in % 1.63 -28.46 -10.93 23.21 -6.87 -30.68 7.22
Balance sheet total 96,753.97 87,383.47 112,656.98 123,810.71 116,848.47 114,665.23 143,577.83
Balance sheet total change in % 10.72 -22.43 -9.01 5.96 1.90 -20.14 10.59

Key Data in CHF

2024 2023 2022 2021 2020 2019 2018
Sales per share 21.78 19.52 21.97 20.88 19.89 20.35 21.67
P/E ratio (year end quote, basic EPS) 17.02 13.21 27.45 8.20 25.14 30.09 15.79
P/E ratio (year end quote, diluted EPS) 17.16 13.30 27.65 8.26 25.35 30.46 15.96
Dividend yield in % 3.95 3.89 3.83 3.86 3.59 3.21 3.39
Equity ratio in % 41.33 45.03 48.80 49.91 42.87 46.91 54.03
Debt ratio in % 58.67 54.97 51.20 50.09 57.13 53.09 45.97

Novartis Dividend Calendar

Date Name Dividend *yield Currency
2024 Novartis AG 3.50 3.95 CHF
2023 Novartis AG 3.30 3.89 CHF
2022 Novartis AG 3.20 3.83 CHF
2021 Novartis AG 3.10 3.86 CHF
2020 Novartis AG 3.00 3.59 CHF
2019 Novartis AG 2.95 3.21 CHF
2018 Novartis AG 2.85 3.39 CHF
2017 Novartis AG 2.80 3.40 CHF
2016 Novartis AG 2.75 3.71 CHF
2015 Novartis AG 2.70 3.11 CHF
2014 Novartis AG 2.60 2.82 CHF
2013 Novartis AG 2.45 3.44 CHF
2012 Novartis AG 2.30 4.00 CHF
2011 Novartis AG 2.25 4.19 CHF
2010 Novartis AG 2.20 4.00 CHF
2009 Novartis AG 2.10 3.72 CHF
2008 Novartis AG 1.89 3.79 USD
2007 Novartis AG 1.42 2.58 USD
2006 Novartis AG 1.11 1.93 USD
2005 Novartis AG 0.88 1.67 USD
2004 Novartis AG 0.92 1.83 USD
2003 Novartis AG 0.81 1.79 USD
2002 Novartis AG 0.69 1.89 USD
2001 Novartis AG 0.54 1.49 USD
2000 Novartis AG 0.53 1.19 USD
1999 Novartis AG 0.50 1.36 USD
*Yield of the Respective Date

Novartis Calendar

Event Estimate Info Date
Earnings Report 2.307 USD Q2 2025 Earnings Release 07/17/2025
Earnings Report 2.117 USD Q3 2025 Earnings Release 10/28/2025
Earnings Report 1.955 USD Q4 2025 Earnings Release 02/04/2026
Earnings Report 2.040 USD Q1 2026 Earnings Release 04/28/2026
Earnings Report 2.120 USD Q2 2026 Earnings Release 07/21/2026
Earnings Report 2.150 USD Q3 2026 Earnings Release 11/03/2026

Novartis Past Events

Event Actual EPS Info Date
Earnings Report 1.645 CHF Q1 2025 Earnings Release 04/29/2025
Annual General Meeting 5.214 CHF Annual General Meeting 03/07/2025
Earnings Report 1.246 CHF Q4 2024 Earnings Release 01/31/2025
Earnings Report 1.369 CHF Q3 2024 Earnings Release 10/29/2024
Earnings Report 1.447 CHF Q2 2024 Earnings Release 07/18/2024
Earnings Report 1.145 CHF Q1 2024 Earnings Release 04/23/2024
Annual General Meeting 6.425 CHF Annual General Meeting 03/05/2024
Earnings Report 3.673 CHF Q4 2023 Earnings Release 01/31/2024
Earnings Report 0.751 CHF Q3 2023 Earnings Release 10/24/2023
Earnings Report 0.998 CHF Q2 2023 Earnings Release 07/18/2023
Earnings Report 1.009 CHF Q1 2023 Earnings Release 04/25/2023
Annual General Meeting 3.047 CHF Annual General Meeting 03/07/2023
Earnings Report 0.665 CHF Q4 2022 Earnings Release 02/01/2023
Earnings Report 0.706 CHF Q3 2022 Earnings Release 10/25/2022
Earnings Report 0.743 CHF Q2 2022 Earnings Release 07/19/2022
Earnings Report 0.924 CHF Q1 2022 Earnings Release 04/26/2022
Annual General Meeting 9.792 CHF Annual General Meeting 03/04/2022
Earnings Report 6.721 CHF Q4 2021 Earnings Release 02/02/2022

Novartis Profile

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Moody’s Daily Credit Risk Score

Risk
  • Low
  • Medium
  • High
1
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

Novartis Management

Name Job
Linda Kanitra Associate Director-Drug Development
Giovanni Caforio Chairman
Kees Roks Chief Audit Officer
Ingrid Zhang Chief Commercial Officer-International
Michelle Weese Chief Corporate Affairs Officer
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Karen L. Hale Chief Legal & Compliance Officer
Shreeram Aradhye Chief Medical Officer & President-Development
Robert Kowalski Chief People & Organization Officer
Aharon Gal Chief Strategy & Growth Officer
Korab Zuka Chief Sustainability Officer
Elizabeth McNally Director
Maria Victoria Cuevas-Pautonnier Director-Investor Relations & Head-ESG
Ton Büchner Independent Non-Executive Director
John D. Young Independent Non-Executive Director
Daniel Hochstrasser Independent Non-Executive Director
Bridgette P. Heller Independent Non-Executive Director
Nancy C. Andrews Independent Non-Executive Director
Ana de Pro Gonzalo Independent Non-Executive Director
Mary Elizabeth Doherty Independent Non-Executive Director
Frans van Houten Independent Non-Executive Director
Patrice Bula Lead Independent Non-Executive Director
Patrick Horber President-International
Steffen Lang President-Operations
Charlotte Pamer-Wieser Secretary
Marco Gadola Senior Auditor
Simon E. Moroney Vice Chairman